HIGHLIGHTS
- What: Our analysis suggests that while both tezepelumab and lebrikizumab might be effective in reducing atopic dermatitis disease activity, tezepelumab increased the EASI-50 by more than 30% that of the tezepelumab-treated group.
- Who: Sultan Akbar from the ATStill University, School of Osteopathic Medicine in Arizona (ATSU-SOMA). have published the Article: Pharmacotherapy of atopic dermatitis: a comparison of clinical response with Lebrikizumab and Tezepelumab, in the Journal: (JOURNAL)
- Future: For this review seemed to have a greater reduction of disease activity than did Further studies with greater sample sizes are needed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.